About
Entvin builds AI agents and an intelligent platform that automate FDA compliance and regulatory workflows for life-sciences companies, serving regulatory, medical affairs, and commercial teams. Its differentiation is purpose-built AI for regulated drug-development workflows, including compliance, documentation, and monitoring tasks.
Market
Entvin competes in life-sciences regulatory intelligence and regulatory-workflow automation, targeting the FDA and broader drug-development compliance burden with AI agents for regulatory, medical-affairs, and commercial teams. Its positioning is more workflow- and developer-oriented than a static intelligence database: it combines document drafting, compliance verification, regulatory monitoring, and real-time insights with an API that normalizes product data from 20+ agencies into structured outputs, while established alternatives such as Cortellis emphasize expert-curated regulatory data.
Primary customers are pharmaceutical and biotechnology companies, especially mid-to-large global firms, with buyers and users in regulatory affairs, medical affairs, commercial teams, and regulatory-technology/AI teams. The API also targets pharma SaaS builders, AI/ML application teams, labeling-workflow owners, and pharmacovigilance organizations that need standardized global regulatory data.
At a Glance
Problem
Entvin addresses the labor-intensive, information-heavy regulatory work that pharmaceutical and life-sciences teams perform to bring products to market and keep them compliant. Regulatory professionals must interpret FDA review files, EMA EPARs, product labels, and changing requirements; draft and verify documents; and monitor regulatory developments. These tasks traditionally consume thousands of hours of skilled professional time, creating compliance costs and slowing drug-development timelines.
The clearest use case is turning regulatory documents and label history into actionable intelligence. Teams may need to understand the reasoning behind a regulator’s final conclusion, compare successive label versions, identify how post-approval evidence changed an indication, or prepare an updated CCDS or product label. Faster answers in these workflows can accelerate regulatory strategy and reduce manual review effort.
Product / Service
Entvin positions itself as an AI-agent platform for FDA compliance across regulatory, medical-affairs, and commercial teams. Its product suite includes Labeling AI and Ads Promo AI, while Ask AI lets users search FDA review documents, EMA EPARs, and product labels to extract relevant insights. The platform is intended to work within existing workflows rather than replace regulatory judgment, assisting with document review, labeling, promotional-material compliance, and decision-making.
Entvin also offers a regulatory-intelligence API that connects to data from more than 20 global agencies. It standardizes regulatory data, supports cross-agency search by products, substances, label sections, and approval status, provides notifications for label and product changes, and exposes REST-based integration for other software. The benefit is a faster, more structured way to perform regulatory intelligence, submission planning, label preparation, monitoring, and compliant content development.
Market
Entvin competes in AI-enabled life-sciences regulatory technology, spanning regulatory intelligence, regulatory-information management, labeling, document review, and medical-legal-regulatory or promotional review. Its adjacent alternatives include established regulatory-information-management vendors such as Ennov and Veeva Vault RIM, which centralize product, registration, submission, correspondence, and commitment data. Entvin’s positioning is more AI-agent- and intelligence-oriented, with specialized labeling, promotional-review, document-search, and API capabilities.
The company is not best characterized as pre-revenue based on the available evidence, but its scale remains difficult to verify. Entvin is YC-backed and a 2025 report described a $500,000 raise; another report cited early enterprise pilot customers and claimed savings of hundreds of hours. GetLatka estimates approximately $5 million in 2024 revenue, but explicitly labels its data as an estimate and says it had not interviewed company management, while the available sources do not provide a verified customer count or named customers. This supports a picture of early commercial traction, not independently confirmed enterprise scale.
Founders & Leadership
Funding History
Y Combinator
Recent News
Fundraise Insider’s 2026 funded-startups list includes Entvin as a San Francisco AI startup and labels its last funding type as Seed. The retrieved listing does not provide a new round amount or funding date for Entvin.
Y Combinator’s 2026 health-tech directory identifies Entvin as an active S2022 startup in San Francisco building AI agents for regulatory teams in the life-sciences industry.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Entvin monetizes its AI service through paid subscriptions following a product-trial period. Its terms state that the trial may be extended or converted into a paid subscription, but no public pricing tiers or rates were found.